Posters & Publications

CEA-Targeted Boltbody™ ISAC, BDC-2034, Drives Preclinical Efficacy Associated With Innate Immune Activation, Phagocytosis, and Myeloid Reprogramming

Presented at: 2022 American Association for Cancer Research (AACR)

Dectin-2 Agonist Antibodies Reprogram Tumor-Associated Macrophages To Drive Anti-Tumor Immunity

Presented at: 2022 American Association for Cancer Research (AACR)

PD-L1-Targeted ISAC Combines Myeloid Cell Activation, Immune-Checkpoint Inhibition and ADCP To Improve Anti-Tumor Efficacy Over Anti-PD-L1 Antibodies in Preclinical Models

Presented at: 2022 American Association for Cancer Research (AACR)

Preliminary Results From a Phase 1/2 Study of BDC-1001, a Novel HER2 Targeting TLR7/8 Immune-Stimulating Antibody Conjugate (ISAC), in Patients (Pts) With Advanced HER2-Expressing Solid Tumors

Presented at: 2021 ESMO Immuno-Oncology Congress

Dectin-2, a Novel Target for Tumor Macrophage Reprogramming in Cancer Immunotherapy

Presented at: 2021 Society for Immunotherapy of Cancer (SITC)

PD-L1-targeted ISAC Combines Myeloid Cell Activation, Immune Checkpoint Inhibition and ADCP to Improve Anti-tumor Efficacy Over Anti-PD-L1 Antibodies in Preclinical Models

Presented at: 2021 Society for Immunotherapy of Cancer (SITC)

BDC-2034: Discovery of a CEA-targeting Immune-Stimulating Antibody Conjugate (ISAC) for Solid Tumors

Presented at: 2021 Society for Immunotherapy of Cancer (SITC)

Preliminary results from a Phase 1/2 study of BDC-1001, a novel HER2 targeting TLR7/8 immune-stimulating antibody conjugate (ISAC), in patients (pts) with advanced HER2-expressing solid tumors

Presented at: 2021 American Society of Clinical Oncology (ASCO)

Phase 1/2 study of a novel HER2 targeting TLR7/8 immune-stimulating antibody conjugate (ISAC), BDC-1001, alone and in combination with anti-PD1 antibody in patients (pts) with HER-2 expressing advanced solid tumors

Presented at: 2021 American Association for Cancer Research (AACR)

Immune-stimulating antibody conjugates elicit robust myeloid activation and durable antitumor immunity

Ackerman SE, et al., Nature Cancer (2020)

Phase 1/2 study of novel HER2-targeting, TLR7/8 immune-stimulating antibody conjugate (ISAC) BDC-1001 as a single agent and in combination with an immune checkpoint inhibitor in patients with advanced HER2-expressing solid tumors

Presented at: 2020 San Antonio Breast Cancer Symposium

Phase 1/2 study of novel HER2-targeting, TLR7/8 immune-stimulating antibody conjugate (ISAC) BDC-1001with or without immune checkpoint inhibitor in patients with advanced HER2-expressing solid tumors

Presented at: 2020 Society for Immunotherapy of Cancer (SITC)

Covalent attachment of a TLR7/8 agonist to tumor-targeting antibodies drives potent anti-tumor efficacy by synergistically activating FcγR- and TLR- signaling and enables safe systemic administration

Presented at: 2020 Society for Immunotherapy of Cancer (SITC)

Systemically administered HER2-targeted ISACs provoke a rapid, local response that engages the innate and adaptive arms of the immune system to eradicate tumors in preclinical models

Presented at: 2020 Society for Immunotherapy of Cancer (SITC)

HER2-targeting TLR 7/8 immune-stimulating antibody conjugates elicit robust myeloid activation and anti-tumor immune responses in a TLR- and FcR-dependent manner

Presented at: 2019 Society for Immunotherapy of Cancer (SITC)

TLR7/8 immune stimulating antibody conjugates elicit robust myeloid activation and durable anti-tumor immunity

Presented at: 2019 American Association for Cancer Research (AACR)

Systemic immunity is required for effective cancer immunotherapy

Spitzer MH et al., Cell (2017)

Allogeneic IgG combined with dendritic cell stimuli induce antitumour T-cell immunity

Carmi Y, et al., Nature (2015)